2 news items
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ADCT
6 May 24
response) was observed among the majority of patients, with mixed histologies including r/r DLBCL, follicular lymphoma (FL) and marginal zone lymphoma (MZL
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADCT
13 Mar 24
-tumor activity among the majority of patients dosed at the first two levels, with mixed histologies including DLBCL, FL and MZL. The Company expects
- Prev
- 1
- Next